N.Y. Times: Doc used stem cells to treat Bartolo Colon’s injured shoulder

16 Comments

It’s not often that a major league pitcher is going to prefer to have arm surgery in the Dominican Republic. It might have been necessary in this case, though.

Bartolo Colon received injections of his own stem cells into his shoulder and elbow to treat a rotator cuff tear and ligament damage in a procedure a year ago, the New York Times reports.

Florida-based doctor Joseph R. Purita said he flew to the Dominican Republic and performed the procedures for free. He added that he has also used human growth hormone in similar procedures, though he didn’t in this case.

MLB is looking into the procedure. The Yankees said they didn’t know about it when they signed Colon to a minor league deal this spring. Colon’s agent only informed the team after learning that the New York Times had contacted Purita and was doing an article. The Yankees then informed the league.

Purita made it clear that his procedures are legal in the United States. He said he uses platelet-rich plasma injections in combination with human growth hormone to treat many ligament injuries and arthritic conditions.

Colon, who didn’t pitch after the procedure last April, has returned to the majors to go 2-1 with a 3.86 ERA in four starts and three relief appearances for the Yankees. If he keeps it up, it’d be his first successful season since he won the Cy Young Award for the Angels in 2005. He went 14-21 with a 5.18 ERA from 2006-09.

RHP Fairbanks, Rays agree to 3-year, $12 million contract

tampa bay rays
Dave Nelson/USA TODAY Sports
0 Comments

ST. PETERSBURG, Fla. — Reliever Pete Fairbanks and the Tampa Bay Rays avoided arbitration when they agreed Friday to a three-year, $12 million contract that could be worth up to $24.6 million over four seasons.

The deal includes salaries of $3,666,666 this year and $3,666,667 in each of the next two seasons. The Rays have a $7 million option for 2026 with a $1 million buyout.

His 2024 and 2025 salaries could increase by $300,000 each based on games finished in the previous season: $150,000 each for 35 and 40.

Tampa Bay’s option price could increase by up to $6 million, including $4 million for appearances: $1 million each for 60 and 70 in 2025; $500,000 for 125 from 2023-25 and $1 million each for 135, 150 and 165 from 2023-25. The option price could increase by $2 million for games finished in 2025: $500,000 each for 25, 30, 35 and 40.

Fairbanks also has a $500,000 award bonus for winning the Hoffman/Rivera reliever of the year award and $200,000 for finishing second or third.

The 29-year-old right-hander is 11-10 with a 2.98 ERA and 15 saves in 111 appearances, with all but two of the outings coming out of the bullpen since being acquired by the Rays from the Texas Rangers in July 2019.

Fairbanks was 0-0 with a 1.13 ERA in 24 appearances last year after beginning the season on the 60-day injured list with a right lat strain.

Fairbanks made his 2022 debut on July 17 and tied for the team lead with eight saves despite being sidelined more than three months. In addition, he is 0-0 with a 3.60 ERA in 12 career postseason appearances, all with Tampa Bay.

He had asked for a raise from $714,400 to $1.9 million when proposed arbitration salaries were exchanged Jan. 13, and the Rays had offered for $1.5 million.

Fairbanks’ agreement was announced two days after left-hander Jeffrey Springs agreed to a $31 million, four-year contract with Tampa Bay that could be worth $65.75 million over five seasons.

Tampa Bay remains scheduled for hearings with right-handers Jason Adam and Ryan Thompson, left-hander Colin Poche, third baseman Yandy Diaz and outfielder Harold Ramirez.